Saudi Arabia Tuberculosis Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Test, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Saudi Arabia · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$39.8 MnPlaceholder estimate
Estimate 2025$42.9 Mn1.7% of the global market
Projected 2034$84.3 Mn 96.6%Adds $41.4 Mn over 9 forecast years
CAGR 2025–20347.8%Faster than 20% of 173 Medical Devices markets here
Key players5
Saudi Arabia is 1.66% of the global market.
In Middle East, the largest is Saudi Arabia (this report) at $42.9 Mn.
Fastest growing: Saudi Arabia (this report) at 7.8% a year.
Saudi Arabia ranks 1st of 2 by size in Middle East.
Market size projection
Saudi Arabia
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$41.4 Mn total, 2026–2034
Year-by-year market size, 2024–2034
Tuberculosis Diagnostics Market market size by year, Saudi Arabia
Year
Market size
Change that year
Since 2025
2024 (estimate)
$39.8 Mn
—
—
2025 (base)
$42.9 Mn
+$3.1 Mn
—
2026 (forecast)
$46.2 Mn
+$3.3 Mn
+7.8%
2027 (forecast)
$49.8 Mn
+$3.6 Mn
+16.2%
2028 (forecast)
$53.7 Mn
+$3.9 Mn
+25.3%
2029 (forecast)
$57.9 Mn
+$4.2 Mn
+35%
2030 (forecast)
$62.4 Mn
+$4.5 Mn
+45.6%
2031 (forecast)
$67.3 Mn
+$4.9 Mn
+56.9%
2032 (forecast)
$72.5 Mn
+$5.2 Mn
+69.2%
2033 (forecast)
$78.2 Mn
+$5.7 Mn
+82.4%
2034 (forecast)
$84.3 Mn
+$6.1 Mn
+96.6%
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
1 in Saudi ArabiaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Saudi Arabia. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Saudi Arabia Tuberculosis Diagnostics Market Analysis Executive Summary
Tuberculosis diagnostics find TB infection and disease using skin tests, blood tests, molecular tests and chest X-ray reading.
Key segments of the tuberculosis Diagnostics market include test (Molecular Tests, Interferon Gamma Release Assays and Skin Tests) and setting (Hospitals, TB Programs and Point of Care).
Saudi Arabia Tuberculosis Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Saudi Arabia Tuberculosis Diagnostics Market Dynamics
Market Growth Drivers
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the tuberculosis Diagnostics market.
Opportunity
Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the tuberculosis Diagnostics market room to grow, especially in emerging markets.
Market Restraints
Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the tuberculosis Diagnostics market.
Competitive Landscape for Tuberculosis Diagnostics Market in Saudi Arabia
The tuberculosis Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Tuberculosis Diagnostics Market in Saudi Arabia
Tuberculosis Diagnostics in Saudi Arabia: rules, payment and research
Medical devices need marketing authorisation from the Saudi Food and Drug Authority (SFDA).[1] Citizens get free public care through the Ministry of Health, while most expatriate workers must have private health insurance, regulated by the Council of Health Insurance (CHI).[2] ClinicalTrials.gov lists 1 study on Tuberculosis Diagnostics that is recruiting, active or about to start in Saudi Arabia.[3] Tuberculosis new cases: 8 per 100,000 people in 2024, the latest WHO figure for Saudi Arabia.[4]
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how tuberculosis Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Saudi Arabia.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Test
4.2 By Setting
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Cepheid (Danaher)
7.2 QIAGEN
7.3 Molbio Diagnostics
7.4 Qure.ai
7.5 Revvity
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The tuberculosis Diagnostics market can be segmented based on various criteria, including test, setting and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: WHO Prequalification, Vaccines, tests and medicines on the WHO prequalified lists that match this market. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Tuberculosis Diagnostics right now, from free public sources.
Tuberculosis new cases: 8 per 100,000 people (2024). World: 131 per 100,000 people (2024). 6th highest of the 9 countries we cover in Middle East.[1]
Health spending per person: 1,825 US$ per person (2023). World: 1,317 US$ per person (2023). 2nd highest of the 9 countries we cover in Middle East.[2]
Doctors: 3.41 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). Highest of the 9 countries we cover in Middle East.[3]
[1]World Bank Open Data, Tuberculosis new cases (per 100,000 people). Retrieved 15 Nov 2026.
[2]World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
How big is the Tuberculosis Diagnostics market in Saudi Arabia?
Placeholder estimate: about $42.9 Mn in 2025, rising to about $84.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Tuberculosis Diagnostics market in Saudi Arabia growing?
Placeholder estimate: about 7.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Tuberculosis Diagnostics market report cover?
The report splits the market by test (Molecular Tests, Interferon Gamma Release Assays, Skin Tests, Sputum Smear and more), setting (Hospitals, TB Programs, Point of Care) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Tuberculosis Diagnostics market?
Key players include Cepheid, Qiagen N.V., Molbio Diagnostics, Qure.ai and Revvity.
What is driving the Tuberculosis Diagnostics market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the tuberculosis Diagnostics market.
Who regulates Tuberculosis Diagnostics in Saudi Arabia?
Medical devices need marketing authorisation from the Saudi Food and Drug Authority (SFDA). Source: Saudi Food and Drug Authority. Checked 14 Nov 2026.
How is healthcare paid for in Saudi Arabia?
Citizens get free public care through the Ministry of Health, while most expatriate workers must have private health insurance, regulated by the Council of Health Insurance (CHI). Source: Council of Health Insurance. Checked 14 Nov 2026.
How many clinical trials on Tuberculosis Diagnostics are running in Saudi Arabia?
1 study is recruiting, active or about to start in Saudi Arabia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Saudi Arabia. Retrieved 12 Nov 2026.
What does WHO report for Saudi Arabia?
Tuberculosis new cases: 8 per 100,000 people in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Tuberculosis new cases (per 100,000 people). Retrieved 15 Nov 2026.
How many people in Saudi Arabia are 65 or older?
3.1% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
Saudi Arabia 
US
China
Canada
Japan
Germany
France
UK
Italy
Ecuador
Spain
Brazil
India
Mexico
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya
Roche